Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about the company’s prospects, owing to the stability of its recurring royalty business that generated about $250 million in 2025.
Copyright: dolgachov / 123RF Stock Photo
The research firm expects the royalty recurring business to provide significant stock protection. That’s in part because the company is increasingly investing to grow the royalty revenue base in the Specialty Therapeutics segment. The segment boasts $175 million in trailing-12-month revenue.
Innoviva also owns a large equity stake of about 70% in Armata Pharmaceuticals, which is also expected to drive long-term growth and differentiation. The company also remains well capitalized, with multiple value-accretive capital deployment opportunities across the current business, novel assets, and capital strategies.
Innoviva, Inc. (NASDAQ:INVA) is a diversified holding company that manages a portfolio of biopharmaceutical royalties and invests in, develops, and commercializes healthcare assets. Its core business focuses on royalties from respiratory products (RELVAR®/BREO® and ANORO® ELLIPTA®) partnered with GSK, alongside a specialized therapeutic platform, Innoviva Specialty Therapeutics, focused on critical care and infectious diseases.
While we acknowledge the potential of INVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Oversold Canadian Stocks to Invest In and 10 Best Stocks to Buy in 2026 According to Billionaire George Soros.
Disclosure: None. Follow Insider Monkey on Google News.
